Critical Contrast: MeiraGTx (NASDAQ:MGTX) & Xenetic Biosciences (NASDAQ:XBIO)

MeiraGTx (NASDAQ:MGTX) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Profitability

This table compares MeiraGTx and Xenetic Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Analyst Ratings

This is a summary of recent ratings and recommmendations for MeiraGTx and Xenetic Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0	3	5	1	2.78
Xenetic Biosciences	1	0	0	0	1.00

MeiraGTx currently has a consensus target price of $24.71, indicating a potential upside of 129.05%. Given MeiraGTx’s stronger consensus rating and higher probable upside, equities research analysts clearly believe MeiraGTx is more favorable than Xenetic Biosciences.

Earnings and Valuation

This table compares MeiraGTx and Xenetic Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39 million	12.73	-$114.20 million	$0.71	15.20
Xenetic Biosciences	$3.26 million	1.57	-$2.68 million	($1.16)	-1.93

Xenetic Biosciences has lower revenue, but higher earnings than MeiraGTx. Xenetic Biosciences is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

MeiraGTx has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500.

Institutional & Insider Ownership

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

MeiraGTx beats Xenetic Biosciences on 12 of the 15 factors compared between the two stocks.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.